Exchange: NASDAQ·Updated 07:30 PM EDT
JAZZ logo

JAZZ Jazz Pharmaceuticals plc

$210.50
$4.19
(1.95%)
Today
Closed $210.23
$0.27
(0.13%)
After Hours
EarningsNov 4
Mkt Cap$13.65B
Vol636,712.00

About JAZZ

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.
47

Neutral Sentiment

How do you feel about JAZZ?

topstockalerts
Jim Cramer offered mixed assessments of five stocks during CNBC’s “Mad Money” Lightning Round, highlighting opportunities in pharmaceuticals while warning about interest-rate risks and reassessing a potential takeover scenario. Cramer expressed support for Jazz Pharmaceuticals, saying he was willing to invest despite the stock’s speculative nature. He noted that the company is profitable, suggesting its financial performance provides some support for the investment case even as uncertainty remains. Jazz shares were trading at $218.42, down 1.81% during Friday’s session. Cramer also revisited EchoStar after a report suggested that SpaceX could make a takeover bid for the satellite communications company. Although he had previously been skeptical of EchoStar, he said the potential transaction was compelling enough that he could not ignore it. However, the report did not confirm that SpaceX had made a formal offer, leaving the possibility speculative. $JAZZ $APLE $ECHO $SPCX
3
investpapaya
$JAZZ Okay, fair enough. it got stuck at 135-150. Let's find some buyers at 110! No need to drift lower. Top quality stock. Under 200 a great bargain, if it comes to that....
1

Advertisement|Remove ads.